이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

VBI Vaccines 관리

관리 기준 확인 4/4

VBI Vaccines' CEO는 Jeff Baxter, May2016 에 임명되었습니다 의 임기는 8.08 년입니다. 총 연간 보상은 $ 893.55K, 78.1% 로 구성됩니다. 78.1% 급여 및 21.9% 보너스(회사 주식 및 옵션 포함). 는 $ 12.07K 가치에 해당하는 회사 주식의 0.071% 직접 소유합니다. 12.07K. 경영진과 이사회의 평균 재임 기간은 각각 6.8 년과 6.4 년입니다.

주요 정보

Jeff Baxter

최고 경영자

US$893.5k

총 보상

CEO 급여 비율	78.1%
CEO 임기	8.2yrs
CEO 소유권	0.07%
경영진 평균 재임 기간	6.8yrs
이사회 평균 재임 기간	6.5yrs

최근 관리 업데이트

Recent updates

VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings

Aug 26

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

Jun 17

Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

Jun 09

Is VBI Vaccines (NASDAQ:VBIV) Using Debt Sensibly?

Jan 24

VBI Vaccines: Hepatitis Vaccine Approval Can Be A Catalyst For >$1bn Valuation

Oct 31

CEO 보상 분석

Jeff Baxter 의 보수는 VBI Vaccines 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$84m
Dec 31 2023	US$894k	US$698k	-US$94m
Sep 30 2023	n/a	n/a	-US$115m
Jun 30 2023	n/a	n/a	-US$119m
Mar 31 2023	n/a	n/a	-US$120m
Dec 31 2022	US$2m	US$678k	-US$113m
Sep 30 2022	n/a	n/a	-US$111m
Jun 30 2022	n/a	n/a	-US$102m
Mar 31 2022	n/a	n/a	-US$73m
Dec 31 2021	US$3m	US$605k	-US$70m
Sep 30 2021	n/a	n/a	-US$66m
Jun 30 2021	n/a	n/a	-US$63m
Mar 31 2021	n/a	n/a	-US$56m
Dec 31 2020	US$2m	US$535k	-US$46m
Sep 30 2020	n/a	n/a	-US$42m
Jun 30 2020	n/a	n/a	-US$45m
Mar 31 2020	n/a	n/a	-US$49m
Dec 31 2019	US$1m	US$500k	-US$55m
Sep 30 2019	n/a	n/a	-US$63m
Jun 30 2019	n/a	n/a	-US$62m
Mar 31 2019	n/a	n/a	-US$66m
Dec 31 2018	US$1m	US$465k	-US$64m
Sep 30 2018	n/a	n/a	-US$56m
Jun 30 2018	n/a	n/a	-US$50m
Mar 31 2018	n/a	n/a	-US$43m
Dec 31 2017	US$826k	US$450k	-US$39m

보상 대 시장: Jeff 의 총 보상 ($USD 893.55K )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 697.54K ).

보상과 수익: Jeff 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Jeff Baxter (63 yo)

8.2yrs

테뉴어

US$893,547

보상

Mr. Jeffery R. Baxter, also known as Jeff, FCMA, has been the Chief Executive Officer and President of VBI Vaccines Inc. since May 2016. Mr. Baxter has been the Chief Executive Officer and President of VBI...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jeffery Baxter	President	8.2yrs	US$893.55k	0.071% $ 15.2k
Nell Beattie	CFO, Head of Corporate Development & Director	1.3yrs	데이터 없음	0.0079% $ 1.7k
David Anderson	Chief Scientific Officer	8.2yrs	US$564.56k	0.017% $ 3.7k
Francisco Diaz-Mitoma	Chief Medical Officer	8.4yrs	US$549.22k	0.049% $ 10.5k
Nicole Anderson	Director of Corporate Communications & Investor Relations	no data	데이터 없음	데이터 없음
Athena Kartsaklis	Senior VP of Finance	6.8yrs	데이터 없음	데이터 없음
Avi Mazaltov	Global Head of Manufacturing & GM of SciVac	7.2yrs	데이터 없음	0.025% $ 5.3k
Misha Nossov	Senior VP of Global Commercial Supply Strategy & Head of Europe	4.5yrs	데이터 없음	데이터 없음
T. Buckley	Senior Vice President of Business Development	4.5yrs	데이터 없음	데이터 없음
John Dillman	Chief Commercial Officer	2yrs	데이터 없음	데이터 없음

6.8yrs

평균 재임 기간

57.5yo

평균 연령

경험이 풍부한 관리: VBIV 의 관리팀은 노련하고 경험 (평균 재직 기간 6.8 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jeffery Baxter	President	8.2yrs	US$893.55k	0.071% $ 15.2k
Nell Beattie	CFO, Head of Corporate Development & Director	1.3yrs	데이터 없음	0.0079% $ 1.7k
Steven S. Gillis	Independent Chairperson of the Board	8.2yrs	US$194.03k	0.0098% $ 2.1k
Denis Burger	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Peter Patriarca	Member of Scientific Advisory Board	6.5yrs	데이터 없음	데이터 없음
Stanley Plotkin	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Damian Braga	Chairperson of the Commercial Advisory Board & Independent Director	4.3yrs	US$105.18k	0% $ 0
Michel De Wilde	Independent Director and Chair of Scientific & Clinical Advisory Board	8.2yrs	US$107.68k	0.0058% $ 1.2k
Blaine McKee	Independent Director	5.5yrs	US$120.18k	0% $ 0
Joanne Cordeiro	Independent Director	5.3yrs	US$127.68k	0% $ 0
Robert Pass	Member of Scientific Advisory Board	6.5yrs	데이터 없음	데이터 없음
Adam Finn	Member of Scientific Advisory Board	6.5yrs	데이터 없음	데이터 없음

6.5yrs

평균 재임 기간

68yo

평균 연령

경험이 풍부한 이사회: VBIV 의 이사회는 경험(평균 재직 기간 6.4 년)으로 간주됩니다.

VBI Vaccines 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Insufficient new directors

VBI Vaccines Inc. Announces the Resignation of Linda C. Bain from the Board of Directors

VBI Vaccines Inc. Announces Appointment of John Dillman as Chief Commercial Officer

VBI Vaccines Inc., Annual General Meeting, Jun 22, 2022

Recent updates

Nasdaq Provides Until July 8 Deadline to VBI Vaccines to Meet Minimum Stockholders' Equity Requirement

VBI Vaccines Inc. Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $8.468289 million.

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. Presents Encouraging Early Tumor Response Data from Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma

VBI Vaccines Inc. announced delayed annual 10-K filing

VBI Vaccines Inc. Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology Annual Meeting

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program

VBI Vaccines Inc. Announces Interim Data from the Phase 1 Clinical Study of its Multivalent Pan-Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines Inc. Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM

Consensus revenue estimates increase by 291%, EPS downgraded

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults

Consensus EPS estimates upgraded to US$4.46 loss

New major risk - Shareholder dilution

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $18 million.

VBI Vaccines Inc. announced that it expects to receive $3 million in funding from Brii Biosciences Limited

VBI Vaccines Inc.(NasdaqCM:VBIV) dropped from Russell 2000 Dynamic Index

VBI Vaccines Inc. Announces Prehevbri® Is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults

Now 21% undervalued after recent price drop

Consensus revenue estimates decrease by 38%, EPS upgraded

Price target decreased by 45% to US$33.00

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 1,377%

Insufficient new directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

VBI Vaccines Inc. Announces Health Canada Approval for Prehevbrio™ for Prevention of Hepatitis B in Adults

No longer forecast to breakeven

VBI Vaccines Presents Additional Phase 1/2A Data from VBI-1901 in Recurrent GBM At the 2022 Society for Neuro-Oncology Annual Meeting

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines: Recent Updates Have Fortified My Long-Term Outlook

VBI Vaccines Inc. Announces Presentation of Physician-Initiated Compassionate Use Data of Its 3-Antigen Hepatitis B Vaccine At the 2022 International HBV Meeting

VBI Vaccines gets up to $100M debt funding from K2 HealthVentures

VBI Vaccines Inc. Announces the Resignation of Linda C. Bain from the Board of Directors

Valneva, VBI Vaccines in pact to launch Hep B vaccine in Europe

VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings

Consensus revenue estimates fall by 32%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Announces Appointment of John Dillman as Chief Commercial Officer

VBI Vaccines Receives Non-Compliance Notice from Nasdaq

VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for Its 3-Antigen Adult Hepatitis B Vaccine

VBI Vaccines Inc. Receives U.S. Food and Drug Administration Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

VBI Vaccines Inc. Announces Updated Phase 2A Tumor Response and Overall Survival Data for VBI-1901

VBI Vaccines Inc. Announces UK MHRA Marketing Authorisation for Prehevbri

Consensus forecasts updated

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Forecast to breakeven in 2024

VBI Vaccines Inc. Announces New Data and Progress of VBI-2900, VBI’s eVLP Coronavirus Program

VBI Vaccines Inc., Annual General Meeting, Jun 22, 2022

VBI Vaccines Inc. Announces PreHevbrio Availability in the United States for the Prevention of Hepatitis B in Adults

Forecast to breakeven in 2024

Consensus revenue estimates fall by 49%

Consensus revenue estimates fall by 49%

No longer forecast to breakeven

Price target decreased to US$6.67

VBI Vaccines Receives Positive CHMP Opinion for 3-Antigen Hepatitis B Vaccine for Immunization Against Hepatitis B Infection in Adults in the European Union

Consensus forecasts updated

VBI Vaccines Inc. Announces Prehevbrio [Hepatitis B Vaccine (Recombinant)] Recommends by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults

Is VBI Vaccines (NASDAQ:VBIV) Using Debt Sensibly?

VBI Vaccines Inc. Announces Dosing of First Patient in Second Phase 2 Study in Chronic Hepatitis B Patients

Forecast to breakeven in 2024